Cabaletta Bio, Inc.
CABA
Rank in Stocks
#15591
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage,... Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
Share Price
$1.50
Last synced: 2026-11-09
Market Cap
$254.32M
Change (1 day)
15.38%
Change (1 year)
-39.27%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Cabaletta Bio, Inc. (CABA)
Category
Healthcare
EPS for Cabaletta Bio, Inc. (CABA)
EPS as of September 2026 TTM: $-1.42
According to Cabaletta Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-1.42. At the end of 2025 the company had an EPS of $-1.64, an increase over its 2024 EPS of $-2.34.
EPS history for Cabaletta Bio, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.42 | -13.41% |
| 2025 | $-1.64 | -29.91% |
| 2024 | $-2.34 | 41.82% |
| 2023 | $-1.65 | -8.84% |
| 2022 | $-1.81 | 0.56% |
| 2021 | $-1.80 | 25.00% |
| 2020 | $-1.44 | -64.62% |
| 2019 | $-4.07 | 384.52% |
| 2018 | $-0.84 | 7,976.92% |
| 2017 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,202.82% |
US
|
|
| $-7.07 | 397.89% |
US
|
|
| $-5.29 | 272.54% |
AU
|
|
| $12.88 | -1,007.05% |
BE
|
|
| $21.56 | -1,618.31% |
NL
|
Questions about Cabaletta Bio, Inc.'s earnings per share (EPS)
What is Cabaletta Bio, Inc.'s earnings per share (EPS)?
Cabaletta Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-1.42, as of Sep 2026.
What was Cabaletta Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, Cabaletta Bio, Inc.'s earnings per share (EPS) was $-1.64, compared with $-2.34 in 2024.
How has Cabaletta Bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cabaletta Bio, Inc.'s earnings per share (EPS) was highest in 2020 ($-1.44) and lowest in 2024 ($-2.34).
How does Cabaletta Bio, Inc.'s earnings per share (EPS) compare with similar companies?
Cabaletta Bio, Inc.'s earnings per share (EPS) ($-1.42) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.